

Hundredth Legislature - First Session - 2007 Committee Statement LB 631

Hearing Date: February 15, 2007

Committee On: Health and Human Services

Introducer(s): (Dierks)

Title: Prohibit interchange of anti-epileptic drugs

Roll Call Vote – Final Committee Action:

Advanced to General File

Advanced to General File with Amendments

X Indefinitely Postponed

Vote Results:

5 Yes Senators Johnson, Erdman, Gay, Pankonin, Stuthman

Senators Hansen, Howard No

Present, not voting

Absent

Proponents: Representing:

Senator Dierks Introducer

Richard J. Baltaro, M.D. PhD Nebraska Medical Association and Practicing

> Nebraska Physicians **Epilepsy Foundation**

Sanjay P. Singh, M.D. **Becky Andricks Epilepsy Foundation** Vic Verni **Epilepsy Foundation**

Representing: Opponents:

Coleen Nielsen Medco

Gary Cheloha Health and Human Services System Michaela Valetin Blue Cross Blue Shield Nebraska **Bob Hallstrom** Nebraska Pharmacists Association

Neutral: Representing:

Summary of purpose and/or changes:

LB 631 relates to the Nebraska Drug Product Selection Act. The bill adds new definitions for "anti-epileptic drug," "epilepsy," and "interchange." The bill would prohibit a pharmacist to

"interchange" an anti-epileptic drug without prior notification and the signed, informed consent of the prescribing practitioner and the patient or patient's parent, legal guardian, or spouse. "Interchange" is defined as "the substitution of one version of an anti-epileptic drug for the anti-epileptic drug originally prescribed, including (a) a generic for the prescribed brand, (b) a brand for the prescribed generic, (c) a generic by one manufacturer for a generic by a different manufacturer, (d) a different formulation of the prescribed anti-epileptic drug, or (e) a different anti-epileptic drug."

Explanation of amendments, if any:	
	Senator Joel Johnson Chairnerson